𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Development and application of high-performance liquid chromatography for the study of two new oxyprenylated anthraquinones produced by Rhamnus species

✍ Scribed by Marcello Locatelli; Salvatore Genovese; Giuseppe Carlucci; Dario Kremer; Marko Randic; Francesco Epifano

Book ID
113536373
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
613 KB
Volume
1225
Category
Article
ISSN
1873-3778

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development and application of high-perf
Development and application of high-performance liquid chromatography for the study of ampelopsin pharmacokinetics in rat plasma using cloud-point extraction
✍ Jun Zhou; Ping Zeng; Hong Hai Tu; Feng Qiao Wang 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 215 KB

## Abstract A simple, rapid and specific method based on cloud‐point extraction (CPE) was developed to determine ampelopsin in rat plasma after oral administration by reversed‐phase high‐performance liquid chromatography. The non‐ionic surfactant Genapol X‐080 was chosen as the extract solvent. Som

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti